Ads
related to: meningococcal encephalitis vaccine cost comparison reviews pictures
Search results
Results From The WOW.Com Content Network
Penbraya is a pentavalent conjugate vaccine developed by Pfizer for the prevention of invasive meningococcal disease in people 10 through 25 years of age. [4] Invasive meningococcal disease, caused by the bacterium Neisseria meningitidis, can lead to serious conditions such as meningitis (inflammation of the brain and spinal cord lining) and sepsis. [5]
NmVac4-A/C/Y/W-135 is the commercial name for a polysaccharide vaccine that protects against meningococcal meningitis caused by Neisseria meningitidis, specifically the serotypes A, C, Y, and W-135. This vaccine is part of a broader group of meningococcal vaccines.
Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. [9] Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. [ 9 ] [ 10 ] The vaccines are between 85 and 100% effective for at least two years. [ 9 ]
The first-of-its-kind shot addresses the five most common causes of meningococcal disease, Pfizer says. Vaccine aimed at preventing meningitis in kids approved by FDA. What happens next?
Penbraya combines components from those two vaccines and is approved for use in individuals 10 through 25 years of age. It is administered as a two-dose series given six months apart.
The first vaccine to prevent meningococcal serogroup B (meningitis B) disease was approved by the European Commission on 22 January 2013. [12] Vaccines offer significant protection from three to five years (plain polysaccharide vaccine Menomune, Mencevax and NmVac-4) to more than eight years (conjugate vaccine Menactra). [13] [14]
[62] [63] In Africa, until recently, the approach for prevention and control of meningococcal epidemics was based on early detection of the disease and emergency reactive mass vaccination of the population at risk with bivalent A/C or trivalent A/C/W135 polysaccharide vaccines, [65] though the introduction of MenAfriVac (meningococcus group A ...
This vaccine is a 2 or 3 dose series, depending on the brand of the vaccine, that is given at 2 and 4 months in the 2 dose series and at 2,4 and 6 months in the 3 dose series. Studies show that this vaccine is 85-98% effective against severe rotavirus disease and is 74-87% effective against rotavirus disease of any severity in the first year ...
Ads
related to: meningococcal encephalitis vaccine cost comparison reviews pictures